Breast cancer: Risk, prevention, & tamoxifen

American Journal of Nursing

Volumn 101, Issue 4, 2001, Pages 26-35

  Machia, Joelle ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGE; AGED; BREAST TUMOR; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MIDDLE AGED; NURSING; QUALITY OF LIFE; REVIEW; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; RISK FACTORS; TAMOXIFEN;

EID: 0040620273     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200104000-00016     Document Type: Article

References (44)

1. Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88.
2. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med 1994;154(6):609-16.
3. Olson RL, Mitchell ES. Self-confidence as a critical factor in breast self-examination. J Obstet Gynecol Neonatal Nurs 1989;18(6):476-81.
4. Kash KM, et al. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992;84(1):24-30.
5. Audrain J, et al. Awareness of heightened breast cancer risk among first-degree relatives of recently diagnosed breast cancer patients. The High Risk Breast Cancer Consortium. Cancer Epidemiol Biomarkers Prev 1995;4(5):561-5.
6. Vernon SW, et al. Factors associated with perceived risk of breast cancer among women attending a screening program. Breast Cancer Res Treat 1993;28(2):137-44.
7. Gail MH, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81(24):1879-86.
8. Miller BA, et al., editors. Racial/ethnic patterns of cancer in the United States, 1988-1992. Bethesda (MD): National Cancer Institute; 1996. NIH Pub. No. 96-4104.
9. National Cancer Institute, editor. SEER cancer statistics review, 1973-1991: tables and graphs. Bethesda (MD): The Institute; 1996. NIH Pub. No. 94-2789.
10. Black WC, et al. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995;87(10):720-31.
11. Easton DF, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. AmJ Hum Genet 1995;56(1):265-71.
12. Harris JR, et al. Breast cancer (1). N Engl J Med 1992;327(5):319-28.
13. Madigan MP, et al. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87(22):1681-5.
14. Costantino JP, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91(18):1541-8.
15. Claus EB, et al. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48(2):232-42.
16. Gross RE. Women at high risk for breast cancer. Am J Nurs 1998;98(4):55-8.
17. Hartmann LC, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340(2):77-84.
18. Jordan VC, editor. Tamoxifen: a guide for clinicians and patients. Huntington (NY): PRR; 1996.
19. Love RR, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326(13):852-6.
20. Ward RL, et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993;22(2):87-94.
21. Kristensen B, et al. Tamoxifen and bone metabolism in post-menopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994;12(5):992-7.
22. Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13.
23. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991;303(6800):435-7.
24. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85(17):1398-406.
25. Castellsague J, et al. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf 1998;18(2):117-23.
26. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999;14(1):55-61.
27. Connelly MT, et al. Patient-identified needs for hormone replacement therapy counseling: a qualitative study. Ann Intern Med 1999;131(4):265-8.
28. Ries L, et al., editors. SEER cancer statistics review, 1973-1993: tables and graphs. Bethesda (MD): National Cancer Institute; 1996.
29. Grady D, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85(2):304-13.
30. Bernstein L, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91(19):1654-62.
31. Fisher B, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86(7):527-37.
32. Fornander T, et al. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85(22):1850-5.
33. Barakat RR, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55(2):164-8.
34. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339(8784):1-15.
35. Reichman BS. Tamoxifen's impact on the management of breast cancer: patient perspectives. Oncology (Huntingt) 1997;11(2Suppl 1):55-8.
36. Day R, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17(9):2659-69.
37. Loprinzi CL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356(9247):2059-63.
38. Stearns V, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11(1):17-22.
39. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Huntingt) 1999;13(6):859-61, 65-6, 71-2 passim.
40. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Huntingt) 1999;13(6):859-61, 65-6, 71-2 passim.
41. Albertazzi P, et al. The effect of dietary soy supplementation on hot flashes. Obstet Gynecol 1998;91(1):6-11.
42. Quella SK, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors. A North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18(5):1068-74.
43. Brzezinski A, Debi A. Phytoestrogens: the "natural" selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999;85(1):47-51.
44. Seidl MM, Stewart DE. Alternative treatments for menopausal symptoms. Systematic review of scientific and lay literature. Can Fam Physician 1998;44:1299-308.